Perspective Therapeutics

Perspective Therapeutics Current Liabilities

The Current Liabilities of Perspective Therapeutics (CATX) as of Oct 23, 2026 is 28.68 M USD. In the previous year, Current Liabilities was 23.32 M USD — a change of 23.00% (higher).

Current Liabilities

28.68 MUSD

YoY

23.00%

Last updated:

Current Liabilities of Perspective Therapeutics is 2025 28.68 M USD. Current Liabilities of Perspective Therapeutics was 2024 23.32 M USD. It decreases by 23.00% higher compared to the previous year.

The Perspective Therapeutics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
2.28 M USD
Jan 1, 2019
2.04 M USD
Jan 1, 2020
2.65 M USD
Jan 1, 2021
3.10 M USD
Jan 1, 2022
2.27 M USD
Jan 1, 2023
2.68 M USD
Jan 1, 2024
23.32 M USD
Jan 1, 2025
28.68 M USD
The Perspective Therapeutics Current Liabilities history
YEARCurrent LiabilitiesYoY
28.68 MUSD+23.00%
23.32 MUSD+771.34%
2.68 MUSD+18.09%
2.27 MUSD-26.93%
3.10 MUSD+17.24%
2.65 MUSD+29.59%
2.04 MUSD-10.29%
2.28 MUSD+47.15%
1.55 MUSD-1.74%
1.57 MUSD+0.07%
1.57 MUSD-9.85%
1.74 MUSD+27.03%
1.37 MUSD+36.06%
1.01 MUSD-2.44%
1.03 MUSD-26.70%
1.41 MUSD-14.95%
1.66 MUSD-8.65%
1.82 MUSD-43.64%
3.22 MUSD+23.89%
2.60 MUSD-88.53%
22.68 MUSD+2,681.77%
815,128.00USD-24.80%
1.08 MUSD+4.89%
1.03 MUSD—
0.00USD-100.00%
1.28 MUSD+4.75%
1.23 MUSD-38.55%
1.99 MUSD-7.42%
2.15 MUSD-3.09%
2.22 MUSD+34.78%
1.65 MUSD+0.42%
1.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Current Liabilities of Perspective Therapeutics is 28.68 M USD in 2025.

Current Liabilities of Perspective Therapeutics changed from 23.32 M USD to 28.68 M USD, representing a 23.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Perspective Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Perspective Therapeutics

All Key Metrics — Perspective Therapeutics